- Home
- SM vs ANIP Comparison
SM vs ANIP Comparison
Compare SM & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SM | ANIP |
|---|---|---|
| Founded | 1908 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | SM | ANIP |
|---|---|---|
| Price | $19.05 | $79.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $33.43 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 6.0M | 554.7K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.33 | 1.67 |
| Revenue | ★ $3,166,673,000.00 | $826,880,000.00 |
| Revenue This Year | $31.11 | $44.35 |
| Revenue Next Year | $87.02 | $11.13 |
| P/E Ratio | ★ $2.99 | $47.77 |
| Revenue Growth | 35.48 | ★ 48.87 |
| 52 Week Low | $17.45 | $54.10 |
| 52 Week High | $41.29 | $99.50 |
Technical Indicators
Market Signals| Indicator | SM | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 42.35 |
| Support Level | $18.53 | $78.10 |
| Resistance Level | $20.16 | $82.60 |
| Average True Range (ATR) | 0.85 | 2.74 |
| MACD | 0.10 | -0.38 |
| Stochastic Oscillator | 51.48 | 11.59 |
Price Performance
Historical ComparisonAbout SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.